RESUMEN
Apoplexy of a pituitary adenoma is a rare and under-diagnosed clinical occurrence. It results from either infarction or haemorrhage into an adenoma of the pituitary gland. Its clinical presentation more often includes rapid development of impaired consciousness, severe headache, visual disturbance and variable association of oculomotor nerve palsy. Meningeal irritation signs are considered very rare and usually not reported as presenting symptoms. A 33-year-old male suffered a pituitary macroadenoma apoplexy, clinically indistinguishable from an infectious meningitis at presentation. Three days after surgery, the patient developed a left ophthalmoplegia due to 3(rd) nerve palsy, which fully resolved within 2 months. A right pterional craniotomy was performed during which complete tumour removal was achieved. In conclusion the authors believe that, despite many reports in the literature, encouraging conservative management in pituitary apoplexy by administering intravenous steroids, surgery should be undertaken in order to avoid eventual visual field defects, relieve pituitary gland compression and prevent a possible recurrent apoplectic episode or tumor re-growth.
Asunto(s)
Adenoma/complicaciones , Meningitis/diagnóstico , Apoplejia Hipofisaria/diagnóstico , Hipófisis/patología , Neoplasias Hipofisarias/complicaciones , Enfermedad Aguda , Adenoma/diagnóstico , Adenoma/fisiopatología , Adulto , Infarto Encefálico/complicaciones , Infarto Encefálico/etiología , Infarto Encefálico/patología , Diagnóstico Diferencial , Cefalea/etiología , Humanos , Hidrocortisona/uso terapéutico , Hipopituitarismo/tratamiento farmacológico , Hipopituitarismo/etiología , Hipopituitarismo/patología , Imagen por Resonancia Magnética , Masculino , Dolor de Cuello/etiología , Procedimientos Neuroquirúrgicos/métodos , Enfermedades del Nervio Oculomotor/etiología , Apoplejia Hipofisaria/etiología , Apoplejia Hipofisaria/fisiopatología , Hipófisis/irrigación sanguínea , Hipófisis/cirugía , Neoplasias Hipofisarias/diagnóstico , Neoplasias Hipofisarias/fisiopatología , Complicaciones Posoperatorias/etiología , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Inconsciencia/etiología , Vómitos/etiologíaRESUMEN
UNLABELLED: Temozolomide a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas; its efficacy has been demonstrated in both pre-clinical and phase I and II studies. The goal of this study is to determine the activity and safety of temozolomide in improving overall survival (OS), progression-free survival (PFS) and health-related quality of life (HQL) in patient with malignant gliomas. Forty-two patients with newly diagnosed glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma were studied. The mean follow-up period was 12 months. The overall response rate (only responsive patient) for all histological groups was 40%, 10 patients (24%) showed a stabilization of disease. The median PFS and OS was respectively 8.35 and 14.1 months: time to progression was 34 week ranging from 21 to 47. In all patients, treatment with temozolomide was associated with improvement of performance status including the patient showing disease progression: Karnofski score improved in all patients by a minimum of 10, with a median of 20 at 6 months. No patient stopped the treatment due to side-effects, no major adverse events were recorded. CONCLUSION: Temozolomide appears to be an ideal, first-line, single-agent, with a safe profile and demonstrated HQL benefits in patients with high-grade gliomas.
Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Dacarbazina/análogos & derivados , Glioma/tratamiento farmacológico , Anciano , Antineoplásicos Alquilantes/efectos adversos , Neoplasias Encefálicas/mortalidad , Dacarbazina/efectos adversos , Dacarbazina/uso terapéutico , Supervivencia sin Enfermedad , Femenino , Glioma/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Temozolomida , Resultado del TratamientoRESUMEN
We studied the effect of acute administration of the calcium-channel blocker verapamil (VER) in 27 patients with tumoral hyperprolactinemia ([THPRL] prolactinomas and pseudoprolactinomas). We also studied the effect of VER in seven patients with idiopathic hyperprolactinemia (IHPRL) and a small group of patients with normal prolactin (PRL) levels and minimal incidental anomalies shown by magnetic resonance imaging (MRI). The study was performed on 2 separate days: on the first day, all subjects received VER, and on the second they received placebo. Acute administration of VER evoked a remarkable increase in serum PRL in IHPRL (as in normal healthy subjects used as controls), but no response was shown in THPRL, with no overlap between the two conditions. Acute administration of VER stimulated PRL secretion in patients with minimal incidental lesions shown by MRI; however, this increase was smaller in patients whose PRL level consistently reached the upper-normal limit. Although the meaning of such minimal anomalies shown by MRI is unknown, this could suggest that the test is precociously altered. To further elucidate the action of VER on lactotropes, we investigated the effect of VER given intravenously (IV) and compared different oral formulations in healthy subjects. Our data show that the VER test is effective in distinguishing between THPRL and IHPRL, but unfortunately, like other tests, it is not able to individualize patients in whom THPRL is the result of diminished dopaminergic tone (pseudoprolactinoma). From a pathophysiological point of view, calcium influx would appear less important in PRL regulation in chronic disorders of PRL secretion. VER given IV did not stimulate PRL release in normal subjects. This suggests that IV administration could produce a peak with an inadequate duration or that oral formulations may act also by metabolites formed on first-pass metabolism in the liver.
Asunto(s)
Bloqueadores de los Canales de Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/farmacología , Hiperprolactinemia/sangre , Prolactina/sangre , Prolactinoma/complicaciones , Verapamilo/administración & dosificación , Verapamilo/farmacología , Administración Oral , Química Farmacéutica , Humanos , Hiperprolactinemia/etiología , Infusiones Intravenosas , Prolactinoma/sangreRESUMEN
The response of prealbumin was studied in 15 neurosurgical patients following 7 days of enteral nutrition by Nutrisond. Baseline values were compared to day 4 and 7 to assess the degree of change. The prealbumin of day 7 versus baseline value showed a significant increase in the mean serum concentration (16.49 +/- 4.0 vs 19.75 +/- 4.2 mg %). All the patients tolerate well the enteral nutrition with Nutrisond.
Asunto(s)
Encéfalo/cirugía , Nutrición Enteral , Alimentos Formulados , Prealbúmina/metabolismo , Adulto , Anciano , Estudios de Evaluación como Asunto , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Cytogenetic studies on 31 human meningiomas revealed clonal abnormalities in 14 of them. Monosomy 22 was present in three cases as the only abnormality, and in five it was associated with monosomy 18, monosomy 14, loss of X, loss of Y, and trisomy 20, respectively. We found a number of rearrangements involving chromosome #22: an i psu dic(22)(pter----q11::q11----pter) in two cases and a t(18;22)(q12;q11) in another case. Two cases showed a complex translocation involving #7 and #14: t(2;7;14)(q23;q36;q22) and t(1;7;14)(q25;q32;q22), respectively. Other clonal chromosome abnormalities were del(1p) (present in two cases); der(9)t(9;?)(q34;?); der(7)t(7;?)(q31;?); der(22)t(22;?)(q11;?); and a 9p+ chromosome. The relevance for the pathogenesis of human meningiomas of these chromosome anomalies is also discussed with reference to the previous literature. The possible involvement of recessive cancer genes present on the long arm of chromosome #22 is also discussed.
Asunto(s)
Aberraciones Cromosómicas , Genes Recesivos , Neoplasias Meníngeas/genética , Meningioma/genética , Adulto , Anciano , Bandeo Cromosómico , Femenino , Marcadores Genéticos , Humanos , Cariotipificación , Masculino , Persona de Mediana EdadRESUMEN
Empty sella syndrome is an anatomoclinical condition in which the herniation of the chiasmatic cavities inside the sella turcica causes deformation of the bone and compression of the hypophysis and its peduncle, often in association with neurological and endocrine symptoms. Over the past four years 22 patients with primary empty sella syndrome were studied at Pisa University's Department of Neurosurgery with particular emphasis on clinical and radiological pictures and hypophyseal function. Pneumocisternography and computerised tomography of the cranium and cavities were used to verify the diagnosis. Radiology showed alterations to the sella turcica in all cases, principally sellar enlargement, doubled sellar floor and erosion of the clinoid processes. Many patients were obese hypertensives with a long history of headaches. Most of the women revealed amenorrhoea, oligomenorrhoea or early menopause. The study of hypothalamus and hypophysis function shows endocrine alterations in almost all cases.
Asunto(s)
Síndrome de Silla Turca Vacía/diagnóstico por imagen , Sistema Hipotálamo-Hipofisario/fisiopatología , Adolescente , Corticoesteroides/sangre , Adulto , Anciano , Andrógenos/sangre , Síndrome de Silla Turca Vacía/sangre , Síndrome de Silla Turca Vacía/fisiopatología , Estrógenos/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neurohipófisis/fisiopatología , Hormonas Tiroideas/sangre , Tomografía Computarizada por Rayos XRESUMEN
An unusual case of pituitary metastasis from renal cell carcinoma mimicking an adenoma is reported. Panhypopituitarism and chiasmal compression were the first manifestations of the tumor. The clinical, endocrinologic, and pathologic features of pituitary carcinomatous metastasis are discussed.